Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
BEAM reported an insider sale notice on Form 144 for proposed sales of Common Stock by an affiliate. The excerpt shows a restricted stock vesting event of 26,250 shares dated 03/31/2026 and a listed sale by Giuseppe Ciaramella of 35,000 shares for $1,120,041.49.
ETRADE Financial Corporation reported Rule 144 activity involving Common Stock. The filing shows two open-market sales by John M. Evans of 25,000 shares on 01/29/2026 for $734,582.50 and 25,000 shares on 01/30/2026 for $708,946.63. The notice also lists 66,874 shares tied to Restricted Stock Vesting with an effective date of 03/31/2026 described as for services rendered.
BEAM affiliate submitted a Form 144 notice to sell 25,000 shares of Common Stock by stock option exercise on 03/31/2026. The filing lists the sale method as cash and identifies the broker as Morgan Stanley Smith Barney LLC. The excerpt also shows three prior reported sales by the same holder in the past three months: 25,000 shares on 03/30/2026, 25,000 on 01/30/2026, and 25,000 on 01/29/2026, with the dollar amounts shown alongside each sale.
The issuer filed a Rule 144 notice showing a stock option exercise and proposed sale of 25,000 shares of Common stock, dated 03/30/2026. The filing lists two prior sales by John M. Evans on 01/29/2026 and 01/30/2026, each for 25,000 shares at cash amounts shown.
The Vanguard Group filed an amended Schedule 13G/A reporting no beneficial ownership in Beam Therapeutics common stock. The filing states 03/13/2026 and includes a disclosure that Vanguard reorganized on January 12, 2026, after which certain subsidiaries report holdings separately. The amendment is signed on 03/26/2026 and lists 0% ownership and 0 shares beneficially owned.
Beam Therapeutics Inc. terminated its 2019 cross-license agreement with Bio Palette Co., Ltd. as of March 2, 2026, in connection with Bio Palette’s planned dissolution. That agreement had given Beam exclusive, royalty-bearing rights to certain base editing patents for treating human disease worldwide, excluding microbiome products in Asia, while Beam granted Bio Palette exclusive, royalty-bearing rights to use certain Beam base and gene editing patents in the microbiome field in Asia.
Before this termination, Bio Palette and Kobe University ended their own license, which activated a previously arranged standby license between Beam and Kobe. Under this standby license, Kobe directly provides Beam an exclusive license, of the same scope as the original Bio Palette license, to practice specified patents. All rights and licenses between Beam and Bio Palette have now ended, the parties granted each other a mutual release of claims, and no further payments are owed between Beam and Bio Palette under either the termination agreement or the prior license.
Beam Therapeutics President Giuseppe Ciaramella reported insider transactions involving 35,000 shares on Common Stock. He exercised a stock option for 35,000 shares at $17.00 per share, converting a derivative award into directly held Common Stock.
On the same date, he then sold 35,000 shares of Common Stock at a weighted average price of $32.0012 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2025. Following these transactions, he directly owned 190,216 shares of Common Stock and 397,313 shares underlying stock options.
Beam Therapeutics Inc. filed its annual report detailing progress on its base editing platform, clinical pipeline, and major partnerships. The company is advancing multiple programs, including risto-cel for sickle cell disease with a planned biologics license application as early as year-end 2026, BEAM-302 for alpha-1 antitrypsin deficiency under an FDA-aligned accelerated approval pathway, and BEAM-301 and BEAM-304 for rare liver-mediated genetic diseases.
Beam highlights a fully integrated model combining proprietary base editors, lipid nanoparticle and ex vivo delivery, and internal cGMP manufacturing. The report also describes significant collaboration activity, including a liver-targeted candidate licensed to Pfizer, a $200.0 million upfront plus $25.0 million in milestones from Eli Lilly tied to Verve-related rights, and $255.1 million in cash proceeds from the sale of its Orbital Therapeutics stake.